Oligo Metastatic Disease Management with SBRT: A Prospective Observational Study

Objective: For patients with few metastases, including those in difficult-to-reach body locations, stereotactic ablative body radiation (SABR) emerges as a safe and successful treatment. Because it delivers a high dosage to the target tissue and a low dose to the surrounding tissue, stereotactic body radiation therapy (SBRT) is a promising treatment for oligometastatic illness in bone. This study aims to evaluate the treatment's effectiveness and toxicity in individuals with oligometastatic bone disease who have not previously received radiation therapy. Methods: Patients with oligometastatic bone disease—defined as ≤3 active sites of disease—were treated with SBRT. The fractionation schedule and SBRT dose were not required per protocol. There were reports on overall survival, prostate specific antigen progression, local progression-free survival, and progression-free survival. There have also been reports of treatment-related toxicity. Results: This study includes 126 lesions from different tumor histologies and 98 patients in total. Patients were 80.6% male and 19.4% female, with a median age of 72.8 years. 26.7 months was the median follow-up. Prostate cancer was the most prevalent histology (68.4%, 67/98). 27/30 Gy in 3 parts (27.0%, 34/126), 30 Gy in 5 fractions (16.7%, 21/126), or 30/35 Gy in 5 fractions (16.7%, 21/126) were the most often prescribed doses. Dose painting, which uses a greater dose to the gross tumor volume and a lower dose to the clinical target volume, is reflected in multiple doses each treatment regimen. For every patient (3.2%, 4/126), four patients (4.1%, 4/98) had local progression at one site. 2-year local progression-free survival (includes death without local progression) for the complete cohort Patients were 80.6% male and 19.4% female, with a median age of 72.8 years. 26.7 months was the median follow-up. Prostate cancer was the most prevalent histology (68.4%, 67/98). 27/30 Gy in 3 parts (27.0%, 34/126), 30 Gy in 5 fractions (16.7%, 21/126), or 30/35 Gy in 5 fractions (16.7%, 21/126) were the most often prescribed doses. Dose painting, which uses a greater dose to the gross tumor volume and a lower dose to the clinical target volume, is reflected in multiple doses each treatment regimen. For every patient (3.2%, 4/126), four patients (4.1%, 4/98) had local progression at one site. This study includes 126 lesions from different tumor histologies and 98 patients in total. Conclusion: Our research demonstrates that SBRT is both efficacious and tolerable in patients with oligometastatic bone disease, which is consistent with previous research. To ascertain long-term efficacy and toxicity, larger trials are both reasonable and necessary.